A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
4010-01-001
Phase 1 other active
Quick answer
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors for Patients with Advanced Solid Tumors is a Phase 1 program (other) at TESARO Bio Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TESARO Bio Netherlands B.V.
- Indication
- Patients with Advanced Solid Tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active